CWY0 Stock Overview
A clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Clearmind Medicine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.26 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$0.88 |
| Beta | -1.52 |
| 11 Month Change | -7.77% |
| 3 Month Change | 8.73% |
| 1 Year Change | n/a |
| 33 Year Change | -99.72% |
| 5 Year Change | n/a |
| Change since IPO | -99.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| CWY0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | 0.2% |
| 1Y | n/a | -19.3% | 8.5% |
Return vs Industry: Insufficient data to determine how CWY0 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CWY0 performed against the German Market.
Price Volatility
| CWY0 volatility | |
|---|---|
| CWY0 Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: CWY0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CWY0's weekly volatility has decreased from 23% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Adi Zuloff-Shani | www.clearmindmedicine.com |
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction.
Clearmind Medicine Inc. Fundamentals Summary
| CWY0 fundamental statistics | |
|---|---|
| Market cap | €5.18m |
| Earnings (TTM) | -€8.10m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs CWY0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CWY0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.44m |
| Earnings | -US$8.44m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CWY0 perform over the long term?
See historical performance and comparison